<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683876</url>
  </required_header>
  <id_info>
    <org_study_id>201505010014MEBO</org_study_id>
    <nct_id>NCT02683876</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Relationships Between Malodor and Urine Metabolomics</brief_title>
  <official_title>Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mebo Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mebo Research, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify metabolic signatures associated with malodor&#xD;
      conditions. The investigators will perform state-of-the art metabolomics tests and&#xD;
      bioinformatic data mining to explore if conditions leading to malodor can be screened by&#xD;
      metabolomic profiling of urine samples.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, metabolite profiling analysis will be carried out on urine samples of&#xD;
      individuals with malodor conditions related to metabolism inefficiencies. Metabolic profiles&#xD;
      will be identified using the metabolomics equipment located in the NMR, HPLC and MS&#xD;
      facilities of the Metabolomics Innovation Centre (TMIC). Multivariate statistical analyses&#xD;
      will be used, as well as other approaches to mine complex data from heterogeneous sources.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">May 2018</completion_date>
  <primary_completion_date type="Actual">August 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls.</measure>
    <time_frame>time from diagnostic urine sample collection to dispatch of results</time_frame>
    <description>The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor.&#xD;
Differences in metabolite concentrations will be measured by mass spectrometry, to compare urine samples from individuals with malodor issues, and age-matched healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlations Between Urine Biomarkers and Frequency/Severity of Malodor Symptoms (Questionnaires)</measure>
    <time_frame>time from sample collection to notification of results and follow-up needed.</time_frame>
    <description>The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from less severe malodor symptoms. The severity of the disease was assessed trough interviews (frequency of key symptoms) and prior laboratory tests.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Nutritional and Metabolic Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects with malodor</arm_group_label>
    <description>individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>individuals not complaining of uncontrollable or unpredictable malodor episodes</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        individuals complaining of uncontrollable episodes of malodor suspected to be caused by&#xD;
        inefficient body metabolism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  unpredictable and uncontrollable episodes of malodor&#xD;
&#xD;
          -  willing and able to ship a urine sample (in the kit provided) by an overnight courier&#xD;
             to Edmonton, Alberta, Canada&#xD;
&#xD;
          -  good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serious medical conditions that require treatment&#xD;
&#xD;
          -  conditions that, in the opinion of the investigator, would prevent participation&#xD;
&#xD;
          -  under the age of 18&#xD;
&#xD;
          -  elect not to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wishart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Metabolomics Innovation Centre (TMIC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Gabashvili, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MeBo Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MeBO Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Metabolomics Innovation Centre</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.metabolomicscentre.ca/</url>
    <description>The Metabolomics Innovation Centre (TMIC)</description>
  </link>
  <link>
    <url>https://meboresearch.org/</url>
    <description>MeBO Research</description>
  </link>
  <link>
    <url>https://aurametrix.com/NCT2683876</url>
    <description>Gabashvili, I.S. NCT02683876: Documentation of Clinical Trial Data and Procedures.</description>
  </link>
  <reference>
    <citation>Emwas AH, Roy R, McKay RT, Ryan D, Brennan L, Tenori L, Luchinat C, Gao X, Zeri AC, Gowda GA, Raftery D, Steinbeck C, Salek RM, Wishart DS. Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis. J Proteome Res. 2016 Feb 5;15(2):360-73. doi: 10.1021/acs.jproteome.5b00885. Epub 2016 Jan 20. Review.</citation>
    <PMID>26745651</PMID>
  </reference>
  <results_reference>
    <citation>I.S. Gabashvili. Identifying subtypes of a stigmatized medical condition medRxiv 19005223; doi: https://doi.org/10.1101/19005223</citation>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>September 22, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2020</results_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>body odor, malodor, halitosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>to prevent risks of re-identification.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT02683876/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Malodor</title>
          <description>individuals with self-reported socially debilitating odor episodes</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control</title>
          <description>individuals not complaining of uncontrollable or unpredictable malodor episodes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>samples damaged during shipping</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Malodor</title>
          <description>individuals with self-reported socially debilitating odor episodes</description>
        </group>
        <group group_id="B2">
          <title>Healthy Control</title>
          <description>individuals not complaining of uncontrollable or unpredictable malodor episodes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolites measured in urine samples</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="17"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls.</title>
        <description>The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor.&#xD;
Differences in metabolite concentrations will be measured by mass spectrometry, to compare urine samples from individuals with malodor issues, and age-matched healthy controls.</description>
        <time_frame>time from diagnostic urine sample collection to dispatch of results</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Malodor</title>
            <description>individuals with self-reported socially debilitating odor episodes</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control</title>
            <description>individuals not complaining of uncontrollable or unpredictable malodor episodes</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Metabolite Concentrations in Urine Between Individuals With Malodor Issues and Age-matched Healthy Controls.</title>
          <description>The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor.&#xD;
Differences in metabolite concentrations will be measured by mass spectrometry, to compare urine samples from individuals with malodor issues, and age-matched healthy controls.</description>
          <units>uMol/mM creatinine</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arginine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.3" upper_limit="7.9"/>
                    <measurement group_id="O2" value="8.6" lower_limit="1.5" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Citruline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.443" lower_limit="0.175" upper_limit="1.185"/>
                    <measurement group_id="O2" value="0.8" lower_limit="0.2" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymmetric dimethylarginine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.8" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dopamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.10" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.066" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.5" lower_limit="45.4" upper_limit="283.0"/>
                    <measurement group_id="O2" value="101.0" lower_limit="37.0" upper_limit="300.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.016" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.01" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Hydroxytetradecenoylcarnitine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0080" lower_limit="0.001" upper_limit="0.087"/>
                    <measurement group_id="O2" value="0.0020" lower_limit="0.0008" upper_limit="0.0040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="2.3" upper_limit="10.3"/>
                    <measurement group_id="O2" value="17.9" lower_limit="3.6" upper_limit="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlations Between Urine Biomarkers and Frequency/Severity of Malodor Symptoms (Questionnaires)</title>
        <description>The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from less severe malodor symptoms. The severity of the disease was assessed trough interviews (frequency of key symptoms) and prior laboratory tests.</description>
        <time_frame>time from sample collection to notification of results and follow-up needed.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With More Severe Disease</title>
            <description>More severe form of MEBO based on self-reports and prior tests</description>
          </group>
          <group group_id="O2">
            <title>Subjects With Less Severe Disease</title>
            <description>Subjects with less severe symptoms based on self-reports</description>
          </group>
        </group_list>
        <measure>
          <title>Correlations Between Urine Biomarkers and Frequency/Severity of Malodor Symptoms (Questionnaires)</title>
          <description>The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from less severe malodor symptoms. The severity of the disease was assessed trough interviews (frequency of key symptoms) and prior laboratory tests.</description>
          <units>µmol/mmol creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Arginine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="2"/>
                    <measurement group_id="O2" value="3" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Citruline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asymmetric dimethylarginine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2"/>
                    <measurement group_id="O2" value="3" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dopamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                    <measurement group_id="O2" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glycine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146" spread="91"/>
                    <measurement group_id="O2" value="121" spread="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Histamine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.04"/>
                    <measurement group_id="O2" value="0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Hydroxytetradecenoylcarnitine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.028"/>
                    <measurement group_id="O2" value="0.002" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lysine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="3"/>
                    <measurement group_id="O2" value="4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for 6 months after sample collection, 1 year after initial enrollment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Malodor</title>
          <description>individuals with self-reported socially debilitating odor episodes</description>
        </group>
        <group group_id="E2">
          <title>Healthy Control</title>
          <description>individuals not complaining of uncontrollable or unpredictable malodor episodes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maria De la Torre</name_or_title>
      <organization>MEBO Research</organization>
      <phone>7862286880</phone>
      <email>maria.delatorre@meboresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

